Currax Pharmaceuticals LLC’s Post

Kettering Health article provides a balanced overview of semaglutide's benefits and potential drawbacks for weight loss. Dr. Brown's insights on the medication's effectiveness and side effects are valuable for patients considering this treatment option. However, the article doesn't address the significant barriers of cost and availability that many patients face when seeking semaglutide treatments. This is where PVpharma can make a crucial difference. We've partnered with a leading drug manufacturer to provide pharmaceutical-grade semaglutide at just $199/month for any dose - a fraction of typical retail costs. Our state-of-the-art production ensures consistent quality and reliable supply, addressing the shortages many pharmacies experience. For healthcare providers reading this: We can help you offer your patients an affordable, high-quality semaglutide option. This allows you to provide effective weight loss and diabetes management solutions without the typical cost barriers. For patients: If you're interested in semaglutide treatment but concerned about cost or availability, ask your healthcare provider about PVpharma's offering. Our goal is to make this innovative treatment accessible to all who need it, supporting the lifestyle modifications Dr. Brown emphasizes as crucial for long-term success. Contact PVpharma today to learn how we can support your practice or treatment journey with our reliable, affordable semaglutide supply. https://lnkd.in/erktmsic #AffordableSemaglutide #WeightLossSolutions #HealthcareAccess

Kettering Health article provides a balanced overview of semaglutide's benefits and potential drawbacks for weight loss. Dr. Brown's insights on the medication's effectiveness and side effects are valuable for patients considering this treatment option. However, the article doesn't address the significant barriers of cost and availability that many patients face when seeking semaglutide treatments. This is where PVpharma can make a crucial difference. We've partnered with a leading drug manufacturer to provide pharmaceutical-grade semaglutide at just $199/month for any dose - a fraction of typical retail costs. Our state-of-the-art production ensures consistent quality and reliable supply, addressing the shortages many pharmacies experience. For healthcare providers reading this: We can help you offer your patients an affordable, high-quality semaglutide option. This allows you to provide effective weight loss and diabetes management solutions without the typical cost barriers. For patients: If you're interested in semaglutide treatment but concerned about cost or availability, ask your healthcare provider about PVpharma's offering. Our goal is to make this innovative treatment accessible to all who need it, supporting the lifestyle modifications Dr. Brown emphasizes as crucial for long-term success. Contact PVpharma today to learn how we can support your practice or treatment journey with our reliable, affordable semaglutide supply. https://bit.ly/4bxsp8r #AffordableSemaglutide #WeightLossSolutions #HealthcareAccess

NHS England Proposes Phased Rollout of Tirzepatide for Obesity Treatment NHS England has initiated a consultation on the phased rollout of tirzepatide, a new treatment for obesity, prioritizing patients with the highest clinical need. Up to 250,000 people are expected to benefit from this treatment over three years, with support from community-based and digital services. Developed by Eli Lilly and Company, tirzepatide has demonstrated significant weight loss benefits in clinical trials. NICE - National Institute for Health and Care Excellence is evaluating feedback on the proposed plan before issuing final guidance, while NHS England aims to manage the growing demand for obesity treatment and reduce related healthcare costs. For more details please click the link! https://lnkd.in/de4fv9mb #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

I found this article really interesting. It shows that diabetes medication could be a lot cheaper than we are currently experiencing. 💉 🏥 There are many strategies to lower the cost. Insulin pens could be as low as $1.42 (R26) each. For SGLT2s and GLP1s, the treatment cost per month could fall to $1.30 (R24) and $0.75 (R14). 💊 ⚕ #DiabetesEconomics #InsulinAccess #AffordableHealthcare #DiabetesCare #HealthEconomics #SustainablePricing #GlobalHealth #LMICHealthcare #PharmaceuticalPricing #Biosimilars #DrugManufacturingCosts #HealthPolicy #MedicationAffordability #HealthcareCosts #DiabetesManagement #HealthcareInnovation #AccessToMedicine #EquitableHealthcare #PharmaEconomics #HealthcareAccess https://lnkd.in/eik8EtQF

When building a strategy around GLP-1 coverage for weight loss, it's important to rely on real-world data. From Senator Bill Cassidy, in a recent Milken Institute event on the topic, "what comes after the drug? How can we use nutrition here?" A very good question, indeed. We have some experience with that too. Based on our data set treating patients over the last 7 years with Ozempic and other GLP-1 agonist medications, contrary to all other published evidence, it is possible to safely de-prescribe these medications and sustain achieved -10% weight loss at that level for a year or more.

Obesity and diabetes markets are skyrocketing! 📈💊 From $100B to $160B in the next decade, the global obesity market is set to explode. With type 2 diabetes following suit at $70B by 2032, pharma giants are in a race to dominate. Novo Nordisk and Eli Lilly lead the pack with Wegovy and Zepbound, but the competition is fierce. From GLP-1 pathways to oral medications, innovation is the name of the game. The question is: How will this impact your health and wealth? Drop your thoughts below! 👇 #ObesityMarket #DiabetesTreatment #PharmaInnovation

The recent findings from the US FDA staff on the potential risk of low blood sugar associated with Novo Nordisk's weekly insulin raise important considerations for both the medical community and patients managing diabetes. As we advance in the development of innovative treatments, it is crucial to balance the benefits with a comprehensive understanding of the risks. Novo Nordisk's weekly insulin represents a significant stride in simplifying diabetes management, but the flagged risk of hypoglycemia (low blood sugar) warrants careful attention and further investigation. Key points to consider: Patient Education: Ensuring patients are well-informed about the signs of hypoglycemia and how to manage it can mitigate risks. Clinical Monitoring: Regular monitoring and consultations with healthcare providers can help tailor treatment plans to individual needs. Innovation with Caution: As we embrace new therapies, a cautious approach is essential to ensure safety and efficacy. This development is a reminder of the intricate balance in medical advancements and the ongoing need for vigilance and patient-centric care. Let's continue to support innovation while prioritizing patient safety. #DiabetesCare #MedicalInnovation #PatientSafety #Healthcare Feel free to share your thoughts and insights on this critical issue! https://lnkd.in/gzF8cmJd

The ongoing shortage of lower strengths of Novo Nordisk's diabetes medication Ozempic presents a significant opportunity for vials, particularly in the context of meeting the surging demand for diabetes treatments amid production constraints. As the company grapples with manufacturing challenges that are expected to persist through the end of 2024, there could be an increased need for innovative vial solutions that optimize production and distribution processes. Additionally, healthcare professionals are being advised to limit new patient treatments, which may prompt a shift towards alternative delivery systems or formulations. This situation highlights the importance of developing scalable and efficient vial packaging that ensures reliable access to critical medications, ultimately benefiting both manufacturers and patients in a challenging supply landscape.

On #WorldHypertensionDay, Lyrus, a leading pharmaceutical Contract Development and Manufacturing Organization (CDMO), would like to raise awareness about the global burden of #hypertension, also known as high blood pressure. Hypertension is a major risk factor for cardiovascular diseases, such as heart attacks, strokes, and heart failure, which are among the leading causes of death worldwide. According to the World Health Organization (WHO), approximately 1.28 billion adults aged 30-79 years worldwide have hypertension. At Lyrus, we recognize the critical importance of addressing this global health challenge. Through our comprehensive range of services, including formulation development and manufacturing, we are committed to supporting our pharmaceutical partners in developing innovative and effective treatments for hypertension and its associated complications. Our team of experts collaborates closely with our clients, leveraging our state-of-the-art facilities and cutting-edge technologies to advance the development of antihypertensive medications. From development to commercial manufacturing, we ensure strict adherence to quality standards and regulatory guidelines. Furthermore, we understand the importance of patient-centric approaches in managing hypertension. Our expertise in formulation development and drug delivery systems enables us to contribute to improved patient adherence and better treatment outcomes. On this World Hypertension Day, Lyrus reaffirms its commitment to supporting the global healthcare community in addressing this silent killer. Together, we can raise awareness, promote early detection, and facilitate access to effective treatments, ultimately improving the lives of millions of people affected by hypertension worldwide. #WorldHypertensionDay #RaisingAwareness #InnovativeTherapies #PatientCentricApproaches #CDMO #ThinkDesignDeliver #Lyrus  C P Bothra Hemanth bothra Rajesh Goel Elayaraja Natarajan Ramdas Velliyate Jyolsna Agnes Jose Krishna M S Raviraj Kadam

The newest update in weight loss and diabetes prevention! Eli Lilly and Company's popular weight loss drug, tirzepatide, has shown groundbreaking results in a recent long-term study. The drug reduced the risk of developing Type 2 diabetes by a staggering 94% in obese or overweight adults. Not only did participants experience sustained weight loss over three years, but those on the highest dose saw a 22.9% average decrease in body weight. This marks a significant advancement in the fight against obesity and diabetes, showing the potential long-term health benefits of GLP-1 medications like Lilly’s Zepbound and Mounjaro. With more than 1 in 3 Americans facing prediabetes and over 1 million having obesity, these findings could be life-changing and potentially shift future clinical guidelines for managing prediabetes and obesity.  How do you think these findings will impact healthcare? #Healthcare #DiabetesPrevention #Obesity #EliLilly #Pharmaceuticals